The company's low P/E is due to its outlook for shrinking earnings. Investors believe the potential for earnings improvement doesn't justify a higher P/E, limiting the chances of a strong share price rise soon.
Quanex Building Products is undervalued, presenting a good opportunity to increase holdings. The company's future outlook isn't fully reflected in the current share price, making it a good time to invest.
The large scale share sell-off from the Independent Lead Director around current prices raises concern. Lack of recent insider purchases despite significant ownership increases caution towards the company.
Gainers: •$Okta (OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo (STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics (TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals (AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
lightfoot
:
This will be a solid stock and add it to your portfolio. I see NX a growth stock. financials are sound. Sales now. Beware of Biden recession A time to buy like the Mortgage bubble in 2008-9.
Quanex Building Products Stock Forum
In reaction to earnings/guidance:
• $HashiCorp (HCP.US)$ +16.8%, $Lululemon Athletica (LULU.US)$ +9.7%, $PagerDuty (PD.US)$ +5%, $nCino (NCNO.US)$ +3.8% (also Bank Operating System selected by Rabobank Australia and New Zealand), $Broadcom (AVGO.US)$ +2.1%
Other news:
• $Ooma (OOMA.US)$ +3.5% (acquires Junction Networks also reports earnings)
• $Momentus (MNTS.US)$ +3.5% (files for $200 mln mixed securities shelf offering)
• $Humacyte (HUMA.US)$ +2.9% (fi...
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet